Compass Pathways Signals Cautious Rollout as Psychedelic Therapy Nears Regulatory Review
Compass Pathways says it will proceed cautiously as it nears regulatory submission for a psychedelic therapy this quarter.
Compass Pathways says it will proceed cautiously as it nears regulatory submission for a psychedelic therapy this quarter.
A U.K. commission issued 44 recommendations to govern adaptive medical AI, emphasizing staged approvals, performance monitoring and reporting.